Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.

MLA

Stein Gold, Linda, et al. “Long-Term Safety and Effectiveness of Roflumilast Cream 0.3% in Adults with Chronic Plaque Psoriasis: A 52-Week, Phase 2, Open-Label Trial.” Journal of the American Academy of Dermatology, vol. 91, no. 2, Aug. 2024, pp. 273–80. EBSCOhost, https://doi.org/10.1016/j.jaad.2024.03.030.

APA

Stein Gold, L., Adam, D. N., Albrecht, L., Alonso-Llamazares, J., Ferris, L. K., Gooderham, M. J., Hong, H. C.-H., Kempers, S. E., Kircik, L. H., Lebwohl, M., Loo, W. J., Nahm, W. K., Papp, K. A., Stewart, D., Toth, D. P., Zirwas, M., Krupa, D., Snyder, S., Burnett, P., … Berk, D. R. (2024). Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. Journal of the American Academy of Dermatology, 91(2), 273–280. https://doi.org/10.1016/j.jaad.2024.03.030

Chicago

Stein Gold, Linda, David N Adam, Lorne Albrecht, Javier Alonso-Llamazares, Laura K Ferris, Melinda J Gooderham, H Chih-Ho Hong, et al. 2024. “Long-Term Safety and Effectiveness of Roflumilast Cream 0.3% in Adults with Chronic Plaque Psoriasis: A 52-Week, Phase 2, Open-Label Trial.” Journal of the American Academy of Dermatology 91 (2): 273–80. doi:10.1016/j.jaad.2024.03.030.